Articles related to BLADDER CANCER

“We’re lucky to have found it at this stage where I could say the word cure, because I don’t use that word lightly as a cancer doctor.” – Dr. Janet Kukreja, the Director of Urologic Oncology at the CU Cancer Center/UC Health University of Colorado Hospital

“Controlling cancer is, of course, the goal, but there must also be a greater emphasis on life after treatment.”

Company leadership demands FDA explanation for approving identical treatment in patients with CIS while refusing filing for those without CIS, despite same trial data showing comparable clinical benefits and safety profiles.

Workplace exposure to harmful chemicals remains a significant risk factor for bladder cancer, particularly affecting specific occupations and requiring targeted prevention strategies.

The TROPiCs-04 trial results challenge the current treatment landscape for metastatic urothelial carcinoma, highlighting the need for new strategies post-relapse and the importance of next-generation sequencing in patient selection.

This study illuminates the potential of preoperative circulating tumor DNA to redefine the approach to treating high-risk upper tract urothelial carcinoma, offering a nuanced tool for assessing the necessity of neoadjuvant chemotherapy and tailoring patient care.